Welcome to our dedicated page for Liquidia Corporation SEC filings (Ticker: LQDA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Liquidia Corporation (NASDAQ: LQDA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a Delaware corporation focused on biopharmaceutical products for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH‑ILD), Liquidia uses these filings to report financial results, material agreements, governance changes and other significant events.
Investors can review Forms 10‑K and 10‑Q for detailed discussions of Liquidia’s business, including its PRINT® technology platform, the commercialization of YUTREPIA™ (treprostinil) inhalation powder, development of the investigational L606 treprostinil liposome inhalation suspension, and promotion of generic Treprostinil Injection under a profit‑sharing agreement with Sandoz. These periodic reports typically include segment information, research and development spending, risk factors related to PAH and PH‑ILD markets, and descriptions of key contracts.
Current reports on Form 8‑K highlight specific events such as quarterly earnings releases, financing transactions under the revenue interest financing agreement with HealthCare Royalty Partners IV, L.P. (HCR), entry into the exclusive license with Vectura for the nebulizer device used with L606, leases for expanded manufacturing facilities in Morrisville, North Carolina, and outcomes of annual stockholder meetings. Other 8‑K filings may document executive appointments, compensation arrangements and other governance matters.
Users can also monitor proxy statements and Form 4 insider transaction reports to understand board elections, advisory votes on executive compensation and equity awards to officers and directors. Stock Titan’s interface combines these documents with AI‑powered summaries that explain complex sections of long filings, highlight key changes from prior periods and help clarify how new agreements, clinical developments or financing structures may affect Liquidia’s operations and capital structure.
With real‑time updates from EDGAR and structured access to historical filings, this page serves as a central resource for analyzing Liquidia’s regulatory history, capital markets activity and disclosures related to its treprostinil‑based therapies for PAH and PH‑ILD.
Liquidia (LQDA): Form 4 insider activity — The company’s General Counsel reported a conversion of performance stock units and a tax-related sale. On 10/10/2025, 3,758 PSUs converted into an equal number of common shares. On 10/13/2025, 7,839 common shares were sold at $23.41, effected under a Rule 10b5-1 plan adopted on 12/15/2023 and to cover taxes associated with prior RSU and PSU settlements.
Following these transactions, the reporting person directly held 576,017 common shares and had 33,826 derivative securities (PSUs) beneficially owned. An additional 14,500 shares are held indirectly by a spouse. PSU and RSU grants vest on stated schedules, with one-for-one PSU conversion into common stock.
Liquidia (LQDA) officer Michael Kaseta (CFO and COO) reported a Form 4 showing equity settlement and a tax-related sale. On 10/10/2025, he acquired 5,828 shares of common stock upon the conversion of performance stock units, which convert one-for-one into common stock. On 10/13/2025, he sold 11,630 shares at $23.41 per share pursuant to a Rule 10b5-1 plan.
The filing states the sale was made to cover taxes from the settlement of previously granted RSUs and PSUs. Following the transactions, Kaseta beneficially owned 352,646 shares directly. The derivative table lists 52,453 derivative securities beneficially owned after the reported transactions.
Amendment corrects previously omitted indirect holdings: Dr. Stephen M. Bloch, a director of Liquidia Corp (LQDA), amended a prior Form 4 to include 2,917,169 shares of common stock reported as indirectly held through Canaan VIII L.P. The filing states these shares are held by Canaan LP, whose sole general partner is Canaan Partners VIII LLC; investment and voting decisions are made by the managers of Canaan LLC. The Reporting Person disclaims beneficial ownership except for any pecuniary interest from his LLC interest. No derivative securities are reported in this amendment.
Raman Singh, a director of Liquidia Corp (LQDA), exercised stock options and sold a portion of the resulting shares on 09/15/2025. He exercised a non-qualified option with a $2.51 strike to acquire 25,524 shares and a separate option with a $2.59 strike to acquire 20,000 shares. On the same date he sold 45,524 shares at a volume-weighted average price of $25.81, leaving him with beneficial ownership of 31,255 shares. The filing also discloses 18,396 restricted stock units granted on June 17, 2025 that had not vested as of the report date.
Insider sale notice for LQDA: The filing reports a proposed sale of 45,524 common shares on 09/15/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,175,042.73. The shares were acquired the same day via stock option exercise and paid for in cash. The filing shows 86,091,454 shares outstanding for the issuer. It also discloses a recent sale of 7,500 shares on 09/03/2025 generating $220,650.00 in gross proceeds. The signer certifies no undisclosed material adverse information.
Raman Singh, a director of Liquidia Corporation (LQDA), reported a sale of common stock. The Form 4 shows a transaction dated 09/03/2025 where the reporting person sold 7,500 shares at a price of $29.42 each, leaving 31,255 shares beneficially owned after the sale. The filing notes the total includes 18,396 restricted stock units granted on June 17, 2025 that have not vested as of the Form 4 date. The Form 4 is signed by Raman Singh on 09/05/2025.
Liquidia Corporation (LQDA) filed a Form 144 disclosing a proposed sale of 7,500 common shares with an aggregate market value of $220,650. The shares are to be sold through Morgan Stanley Smith Barney LLC on NASDAQ, with an approximate sale date of 09/03/2025. The securities were acquired as Restricted Stock Units from Liquidia Corporation on 06/16/2025, and the filing reports payment/vesting on that same date. The filing shows 86,091,454 shares outstanding. The form indicates no securities sold by the same person in the past three months. Several standard filer and issuer contact fields in the submitted tables appear blank.
Scott Moomaw, Chief Commercial Officer of Liquidia Corporation (LQDA), reported multiple equity transactions. On 08/29/2025 he received 1,875 restricted stock units (RSUs) that convert one-for-one into common shares, increasing his RSU holdings. On 09/02/2025 he sold a total of 70,692 shares in three transactions: 692 shares at $29.05 and 8,315 plus 61,685 shares at a volume-weighted average price of $28.6224. The Form 4 notes the sales were effected pursuant to Rule 10b5-1 trading plans and some shares were sold to cover taxes related to RSU settlements. Following these transactions he beneficially owned 155,254 common shares (direct).
Russell Schundler, General Counsel of Liquidia Corporation (LQDA), reported multiple transactions in company equity. On 08/29/2025, 2,344 restricted stock units (RSUs) vested and converted into 2,344 shares. On 09/02/2025, 1,063 shares were sold at $29.05 per share under a Rule 10b5-1 plan to cover taxes related to RSU settlement. After these transactions, Schundler beneficially owned 580,098 shares directly and 14,500 shares indirectly (by spouse), for a total of 594,598 shares reported. The filing notes multiple prior RSU grants (2022, 2023, 2024, 2025) with portions unvested and 11,869 shares held under the employee stock purchase plan.
Liquidia Corporation insider Sarah Krepp, Chief Human Resource Officer, reported a small disposition of company common stock under a Rule 10b5-1 trading plan. The Form 4 shows a sale on 08/29/2025 of 209 shares at $29.05 per share, executed pursuant to a 10b5-1 plan adopted December 15, 2023, and the transaction was to cover taxes on RSU settlements. After the sale, Krepp beneficially owns 143,130 shares, including multiple unvested RSU tranches (specified amounts) and 5,312 shares from the 2020 Employee Stock Purchase Plan.